THIS WEEK IN OBESITY: Gibson and Dr. Perreault discuss the possibility or lack thereof that we can prevent and/or reverse diabetes and obesity. March 6, 2025
THIS WEEK IN OBESITY: Dr. Gibson and Dr. Perreault discuss the concept that there may or may not be an obesity set point throughout various stages of life. March 4, 2025
Dr. Gibson and Dr. Perreault discuss her PATHWEIGH study for pragmatic weight management in primary care. February 28, 2025
THIS WEEK IN NEPHROLOGY: Dr. Parikh and I discuss the definition and implementation of the Four Pillars of Care in patients with renal insufficiency. February 26, 2025
Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss best practices for titration of GLP-1 medications for optimal weight loss. February 17, 2025 Disclosures: TBD
Dr. McGuire, Dr. Jastreboff, and Dr. C. Michael Gibson discuss new oral semaglutide and the SOUL trial which lowered death, MI and stroke rates by 14% in patients with diabetes. December 18, 2024 Disclosures: TBD
Dr. McGuire, Dr. Jastreboff and Dr. C Michael Gibson discuss the SURMOUNT 1 Trial of Tirzepatide and how we may be able to diminish the progression from pre-diabetes to diabetes. December 9, 2024 Disclosures: TBD
von Willebrand factor molecules cross link and form a net around a blood clot holding it together. Drs. Shahid Nimjee and Gibson discuss a new vWf inhibitor that breaks apart this net & opening closed arteries but leaving a patch of fibrin strands across the site of plaque rupture which would have been dissolved by fibrinolytics potentially causing bleeding. December 4, 2024 Disclosures: TBD
Dr. Stephen Nicholls and Dr. C. Michael Gibson Discuss: Safety and Efficacy of Obicetrapib in Patients With Heterozygous Familial Hypercholesterolemia (BROOKLYN) November 18, 2024 Disclosures: TBD
Dr. Katherine R Tuttle and Dr. C. Michael Gibson Discuss: Benefits of Semaglutide on Chronic Kidney Disease Outcomes by Cardiovascular Status or Risk in the FLOW trial November 18, 2024 Disclosures: TBD
